Symbicort Onset of Action 2

AstraZeneca48 enrolled

Overview

The purpose of this study is to compare the early onset of effect of Symbicort compared to Advair Diskus and Ventolin in adults with asthma

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

DOUBLE

Enrollment

Conditions

Asthma

Interventions

budesonide/formoterolDRUG

fluticasone/salmeterolDRUG

albuterolDRUG

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * At least 18 years of age * Diagnosis of asthma and baseline lung function test results as determined by the protocol * Required and received inhaled corticosteroids within timeframe and doses specified in the protocol Exclusion Criteria: * Severe asthma or asthma that is markedly effected by seasonal factors * Has required and received non-inhaled corticosteroids within the previous 4 weeks, has sensitivity to drugs specified in the protocol or requires treatment with beta-blockers

Outcomes

Primary Outcomes

FEV1 3 minutes post dose

Time frame: 4 assessments across 4 visits whilst on treatment (visits may be between 3 and 14 days apart)

Secondary Outcomes

12 hour serial FEV1

Time frame: 4 assessments across 4 visits whilst on treatment (visits may be between 3 and 14 days apart)

Patients perception of effect

Time frame: Patients perception of effect

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.